Orforglipron
Weight management and glycemic control; oral convenience as the key differentiator from injectable GLP-1 class
Orforglipron (LY3502970) is an oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a once-daily tablet that does not require refrigeration or injection. Phase 3 trials (ACHIEVE and ATTAIN programs) have demonstrated clinically meaningful reductions in body weight and HbA1c in people with obesity and/or type 2 diabetes. As a small molecule, it avoids the peptide degradation limitations that require co-formulation approaches for other oral GLP-1 attempts (e.g., oral semaglutide). GI side effects (nausea, vomiting, diarrhea) are the primary tolerability concern, consistent with the GLP-1 class.
- Weight Management
- Blood Sugar Support
GLP-1 class cautions (GI effects, gallbladder, pancreatitis signal).
Mechanism of Action
An oral, non-peptide (small-molecule) GLP-1 receptor agonist by Eli Lilly. Activates the GLP-1 receptor to boost glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite. Notable as a once-daily oral tablet, unlike the injectable GLP-1 peptides.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full Orforglipron protocols — frequency, timing, cycle length, reconstitution & research